Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates
- 1 April 1991
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 35 (4), 764-766
- https://doi.org/10.1128/aac.35.4.764
Abstract
The in vitro activities of three new quinolones (sparfloxacin, CI-960, and PD 131,628) were compared with that of ciprofloxacin against 5,252 routine clinical aerobic and facultatively anaerobic bacterial isolates. Overall, CI-960 was the most active drug in vitro (MIC for 90% of the strains tested, 0.13 micrograms/ml); ciprofloxacin and sparfloxacin were the least active (MIC for 90% of the strains tested, 1.0 micrograms/ml). All three new quinolones, but particularly CI-960 and PD 131,628, exhibited significantly greater activity than ciprofloxacin against enterococci and staphylococci.Keywords
This publication has 6 references indexed in Scilit:
- In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agentAntimicrobial Agents and Chemotherapy, 1991
- Comparative in vitro activity of the new quinolone sparfloxacin (CI-978, AT-4140) against nosocomial gram-negative bloodstream isolatesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1990
- In vitro activity of AT-4140 against clinical bacterial isolatesAntimicrobial Agents and Chemotherapy, 1989
- In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinoloneAntimicrobial Agents and Chemotherapy, 1989
- Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivativeAntimicrobial Agents and Chemotherapy, 1988
- The in-vitro activity of PD127,391, a new quinoloneJournal of Antimicrobial Chemotherapy, 1988